Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

9:11 AM ET 8-K
Financial Results Minerva Neurosciences, Inc. NERV

Minerva Neurosciences Financial Results

Minerva Neurosciences reported third quarter 2026 financial results and provided a business update on its ongoing Phase 3 trial (C19 Study) of roluperidone for negative symptoms of schizophrenia. The company expects topline efficacy data from Phase A of the trial in the second half of 2027 and remains focused on developing non-dopaminergic treatments for CNS disorders.

Term
Q3 2026

“The psychiatry field has increasingly recognized the importance of finding non-dopaminergic mechanisms in the treatment of schizophrenia, particularly for negative symptoms. Roluperidone is the only late-stage candidate targeting negative symptoms directly. The C19 study, our ongoing Phase 3 trial, is designed to confirm the effect we saw in our prior trials. We remain focused on execution and on track for topline efficacy data in the second half of 2027.”

Remy Luthringer, Ph.D., Chief Executive Officer of Minerva Neurosciences
9:11 AM ET 10-Q
Financial Results Elanco Animal Health Inc ELAN

Elanco Animal Health Q3 2026 Results: Turns Profitable, Net Income $18M

Elanco Animal Health reported revenue of $1,265 million for the third quarter of 2026, an increase from $1,137 million in the prior year. The company achieved a net income of $18 million for the quarter, recovering from a net loss of $34 million in Q3 2025, driven by higher gross profits and lower restructuring charges.

Key figure
Net income $18M
9:07 AM ET 8-K
Investor Presentation Assured Guaranty Ltd AGO

Assured Guaranty Investor Presentation

Assured Guaranty Ltd. has made available its Fixed Income Investor Presentation for the period ended September 30, 2026, on its corporate website. The company also released the Assured Guaranty Inc. September 30, 2026 Financial Supplement as part of its Regulation FD disclosures.

9:04 AM ET 10-Q
Financial Results Farmers National Banc Corp FMNB

Farmers National Banc Q3 2026 Results: Net Income $14.5M, Up 16.6% YoY

Farmers National Banc Corp. reported net income of $53.8 million for the first nine months of 2026, up from $39.9 million in the prior year, driven by a significant increase in net interest income following a business combination. Total assets grew to $7.1 billion as of September 30, 2026, while the company recorded a substantial unrealized loss on available-for-sale securities of $74.6 million net of tax during the period.

Key figure
Net income $14.5M · +16.6% YoY
9:02 AM ET 10-Q
Financial Results Immunocore Holdings plc IMCR

Immunocore Holdings Q3 2026 Results: Net Loss of $14.2M, Loss Widens

For the nine months ended September 30, 2026, Immunocore reported total revenue of $324.8 million, a 10% increase over the prior year, and a significantly narrowed net loss of $2.1 million compared to $5.5 million in 2025. The company maintained a strong liquidity position with $901.3 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $14.2M
9:01 AM ET 8-K
Financial Results Immunocore Holdings plc IMCR

Immunocore Holdings Financial Results

Immunocore reported Q3 2026 financial results with KIMMTRAK net revenues of $102.2 million and a net loss of $14.2 million. The company highlighted the completion of target enrollment for its Phase 3 TEBE-AM trial in cutaneous melanoma and the first patient dosed in its autoimmune program for type 1 diabetes.

Term
Q3 2026

“Nearly five years after launch, KIMMTRAK remains the proven standard of care in HLA-A*02:01+ metastatic uveal melanoma. With TEBE-AM fully enrolled and data expected in the second quarter of 2027, we are advancing our mission to bring this therapy to even more patients.”

Bahija Jallal, CEO of Immunocore

“Recently, our platform delivered two significant firsts: what we believe is the first data demonstrating clinical activity and a manageable safety profile with the combination of two T cell engagers in a solid tumor, and the first patient dosed in our tissue-specific autoimmune program for type 1 diabetes.”

Bahija Jallal, CEO of Immunocore
8:56 AM ET 10-Q
Financial Results First Financial Bancorp FFBC

First Financial Bancorp Q3 2026 Results: Net Income $81.2M, Up 12.9% YoY

First Financial Bancorp reported net income of $81.2 million for the third quarter of 2026, up from $71.9 million in the prior year period. Total assets grew to $22.3 billion, driven by a 3.6% increase in total loans and leases since year-end 2025, while net interest income for the first nine months of 2026 rose significantly to $576.2 million.

Key figure
Net income $81.2M · +12.9% YoY
8:52 AM ET 8-K
Financial Results United Bancorp Inc UBCP

United Bancorp Financial Results

United Bancorp reported Q3 2026 net income of $1.4 million, or $0.25 per diluted share, which was negatively impacted by a $2.95 million commercial credit charge-off. Despite this one-time event, the company noted that its Pre-Provision Net Revenue (PPNR) increased year-over-year to $3.49 million, driven by investments in infrastructure and growth.

Term
Q3 2026

“During the three-month period ended September 30, 2026, we were impacted by a one-time event that caused earnings to perform below our typical expectations. For the most recently ended quarter, United Bancorp, Inc. (UBCP) produced net income and diluted earnings per share of $1,401,000 and $0.25, respectively.”

Randall M. Greenwood, Senior Vice President, CFO and Treasurer

“Fundamentally and exclusive of the one-time loan charge off experienced this most recent quarter, we are very satisfied with the level at which UBCP is presently performing and firmly believe that the initiatives our Company has undertaken in the last two years are paying off.”

Randall M. Greenwood, Senior Vice President, CFO and Treasurer
8:50 AM ET 10-Q
Financial Results Protagonist Therapeutics, Inc PTGX

Protagonist Therapeutics Q3 2026 Results: Turns Profitable, Net Income $220M

Protagonist Therapeutics reported a significant increase in license and collaboration revenue to $544.3 million for the nine months ended September 30, 2026, resulting in a net income of $386.6 million compared to a net loss in the prior year. The company's cash position strengthened considerably, with total assets reaching $1.15 billion as of the end of the third quarter.

Key figure
Net income $220M
8:50 AM ET 10-Q
Financial Results Green Plains Inc. GPRE

Green Plains Q3 2026 Results: Net Income $85.4M, Up 616.4% YoY

Green Plains Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $186.2 million compared to a net loss of $133.9 million in the prior year period. This improvement was driven by a substantial reduction in cost of goods sold and a sharp increase in production tax credits, which rose to $209.9 million.

Key figure
Net income $85.4M · +616.4% YoY
8:47 AM ET 10-Q
Financial Results XPEL, Inc. XPEL

XPEL Q3 2026 Results: Net Income $16.3M, Up 26.3% YoY

XPEL, Inc. reported a 9.9% increase in total revenue to $137.8 million for the third quarter of 2026, with net income attributable to stockholders rising to $16.3 million. The company significantly increased its property and equipment assets to $95.1 million and took on $42.6 million in long-term debt to support its growth and acquisition strategies.

Key figure
Net income $16.3M · +26.3% YoY
8:46 AM ET 10-Q
Financial Results John Marshall Bancorp, Inc. JMSB

John Marshall Bancorp Q3 2026 Results: Net Income $7.54M, Up 39.5% YoY

John Marshall Bancorp reported net income of $7.5 million for the quarter ended September 30, 2026, an increase from $5.4 million in the prior year period. Total assets grew to $2.44 billion, driven by a $92.0 million increase in total deposits and steady loan growth during the first nine months of the year.

Key figure
Net income $7.54M · +39.5% YoY
8:46 AM ET 10-Q
Financial Results CG Oncology, Inc. CGON

CG Oncology Q3 2026 Results: Net Loss of $56.9M, Loss Widens

CG Oncology reported a net loss of $196.1 million for the first nine months of 2026, driven by a significant increase in research and development expenses to $137.6 million. The company strengthened its balance sheet through a follow-on public offering that raised $391.6 million, ending the period with over $984 million in cash and marketable securities.

Key figure
Net loss $56.9M
8:46 AM ET 10-Q
Financial Results Forrester Research, Inc. FORR

Forrester Research Q3 2026 Results: Net Loss of $4.42M, Loss Widens

Forrester Research reported a net loss of $4.4 million for the third quarter of 2026, with total revenues declining to $86.1 million from $94.3 million in the prior year period. The company's nine-month performance was impacted by a $10.8 million goodwill impairment charge, though this was significantly lower than the $83.9 million impairment recorded in the same period of 2025.

Key figure
Net loss $4.42M
8:45 AM ET 10-Q
Financial Results Assured Guaranty Ltd AGO

Assured Guaranty Q3 2026 Results: Net Income $78M, Down 25.7% YoY

For the nine months ended September 30, 2026, Assured Guaranty Ltd. reported net income attributable to the company of $205 million, a decrease from $384 million in the prior year period. Total assets grew to $12.4 billion, while the company expanded its operations through the acquisition of Assured Life Re and the introduction of annuity reinsurance segments.

Key figure
Net income $78M · -25.7% YoY
8:42 AM ET 10-Q
Financial Results First Citizens Bancshares Inc FCNCA

First Citizens Bancshares Q3 2026 Results: Net Income $606M, Up 6.7% YoY

First Citizens BancShares reported net income of $606 million for the third quarter of 2026, with total assets reaching $241.2 billion. The company experienced a significant increase in total deposits to $185.3 billion, while net interest income saw a slight decrease compared to the prior year's quarter.

Key figure
Net income $606M · +6.7% YoY
8:41 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences announced interim six-month results from its PRECISE-BTN multicenter U.S. study evaluating the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules. The data showed that 86% of patients achieved the primary endpoint of at least 50% nodule volume reduction, with a median reduction of 72% and no serious adverse events reported. These results demonstrate the safety and efficacy of the company's nonthermal Nanosecond Pulsed Field Ablation (nsPFA) technology in a clinical setting.

8:40 AM ET 8-K
Financial Results Plains Gp Holdings LP PAGP

Plains Gp Holdings Financial Results

Plains GP Holdings reported third-quarter 2026 net income of $363 million and Adjusted EBITDA of $711 million. The company highlighted the expansion of its Permian JV gathering system and the $585 million acquisition of the Silver Creek gathering system in the Powder River Basin. Management reaffirmed full-year 2026 Adjusted EBITDA guidance of approximately $2.88 billion.

Term
Q3 2026

“Our company delivered solid operational performance year-to-date with continued execution across the organization on our key initiatives for the year. We are driving efficient growth through multiple avenues including a further expansion of our Permian gathering footprint to service additional acreage in the Midland Basin with a large integrated producer.”

Willie Chiang, Chairman, CEO and President

“The recent junior subordinated notes offering and corresponding redemption of preferred securities is expected to generate distributable cash flow accretion to common unitholders. Finally, the oil macro environment remains volatile, yet constructive, and we see multiple tailwinds for our business as we build momentum into 2027.”

Willie Chiang, Chairman, CEO and President
8:39 AM ET 8-K
Financial Results Plains All American Pipeline LP PAA

Plains All American Pipeline Financial Results

Plains All American reported third-quarter 2026 net income of $363 million and Adjusted EBITDA of $711 million. The company highlighted the completion of its $585 million acquisition of Silver Creek assets and a new Permian JV gathering expansion supported by a 10-year agreement with a large integrated producer. Management reaffirmed full-year 2026 Adjusted EBITDA guidance of approximately $2.88 billion.

Term
Q3 2026

“Our company delivered solid operational performance year-to-date with continued execution across the organization on our key initiatives for the year. We are driving efficient growth through multiple avenues including a further expansion of our Permian gathering footprint to service additional acreage in the Midland Basin with a large integrated producer.”

Willie Chiang, Chairman, CEO and President

“The recent junior subordinated notes offering and corresponding redemption of preferred securities is expected to generate distributable cash flow accretion to common unitholders. Finally, the oil macro environment remains volatile, yet constructive, and we see multiple tailwinds for our business as we build momentum into 2027.”

Willie Chiang, Chairman, CEO and President
8:36 AM ET 8-K
Financial Results Franklin Templeton Inc BEN

Franklin Templeton Financial Results

Franklin Templeton reported preliminary Q4 2026 net income of $380.1 million and full-year net income of $1.08 billion, a significant increase from the prior year. The company achieved record assets under management (AUM) of $1.8 trillion, driven by $84.1 billion in full-year long-term net inflows across all regions and channels.

Term
FY2026

“Franklin Templeton delivered strong fourth quarter and fiscal year 2026 results, reflecting the momentum across our business and continued execution of our strategy. We generated $20.8 billion in long-term net inflows during the fourth quarter, bringing full-year long-term net inflows to $84.1 billion, with positive net flows in every quarter this fiscal year across all regions and in both retail and institutional channels.”

Jenny Johnson, Chief Executive Officer of Franklin Templeton, Inc.
8:32 AM ET 10-Q
Financial Results Community Trust Bancorp Inc CTBI

Community Trust Bancorp Q3 2026 Results: Net Income $25.9M, Up 8.3% YoY

Community Trust Bancorp, Inc. reported its financial results for the third quarter of 2026, showing stable net interest margins and continued growth in its loan portfolio. The company maintained strong capital ratios and asset quality, though it noted slight increases in non-interest expenses related to technology investments.

Key figure
Net income $25.9M · +8.3% YoY
8:31 AM ET 8-K
Financial Results DarkHorse Technologies Inc. DRK

DarkHorse Technologies Financial Results

DarkHorse Technologies reported Q3 2026 results, highlighting a doubling of its contracted power capacity to 100 MW following a new 50 MW agreement in Kentucky. The company is pivoting its strategy toward AI inference infrastructure and 'superintelligence factories' while completing Bitdeer mining installations across three sites.

Term
3 years

“We doubled our contracted power capacity to approximately 100 MW, completed Bitdeer installations across three sites and advanced engineering for our planned superintelligence factories, including an initial basis-of-design package for a Kentucky project and boundary surveys at two of our Kentucky development sites.”

Joel Block, Chief Executive Officer of DarkHorse

“We believe the race in AI infrastructure is to bring usable compute capacity online in 2027. Our focus is inference, where trained AI models serve everyday applications.”

Joel Block, Chief Executive Officer of DarkHorse
8:31 AM ET 10-Q
Financial Results Burke & Herbert Financial Services Corp. BHRB

Burke & Herbert Financial Services Q3 2026 Results: Net Income $36.4M, Up 21.4% YoY

Burke & Herbert Financial Services Corp. reported a net income of $73.2 million for the nine months ended September 30, 2026, a decrease from $87.1 million in the prior year period. Total assets grew significantly to $11.0 billion from $7.9 billion at year-end 2025, primarily driven by a substantial increase in net loans and the acquisition of goodwill and intangible assets.

Key figure
Net income $36.4M · +21.4% YoY
8:31 AM ET 8-K
Financial Results CG Oncology, Inc. CGON

CG Oncology Financial Results

CG Oncology reported third quarter 2026 financial results, highlighting a cash position of $984.5 million which is expected to fund operations through 2029. The company is approaching several clinical milestones, including anticipated Phase 3 topline data for PIVOT-006 in November 2026 and the completion of its BLA submission for BCG-unresponsive NMIBC in Q4 2026.

Term
Q3 2026

“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.”

Arthur Kuan, Chairman, President & Chief Executive Officer
8:31 AM ET 10-Q
Financial Results Tanger Inc. SKT

Tanger Q3 2026 Results: Net Income $33.6M, Up 5.1% YoY

Tanger Inc. reported net income attributable to the company of $95.2 million for the nine months ended September 30, 2026, an increase from $81.3 million in the prior year period. Total revenues grew to $464.5 million, driven primarily by higher rental revenue, while the company managed a significant shift in its debt structure, including the issuance of senior unsecured exchangeable notes.

Key figure
Net income $33.6M · +5.1% YoY
8:31 AM ET 10-Q
Financial Results Tanger Properties Ltd Partnership

Tanger Properties Ltd Partnership Q3 2026 Results: Net Income $33.6M, Up 5.1% YoY

For the nine months ended September 30, 2026, Tanger Inc. reported total revenues of $464.5 million, an increase from $421.3 million in the prior year period. Net income attributable to Tanger Inc. grew to $95.2 million compared to $81.3 million in 2025, driven by higher rental revenue and equity in earnings from unconsolidated joint ventures.

Key figure
Net income $33.6M · +5.1% YoY
8:31 AM ET 8-K
Business Update BioCardia, Inc. BCDA

BioCardia Business Update

BioCardia has completed the clinical consultation process with Japan's PMDA regarding application materials for its CardiAMP Cell Therapy System. This milestone allows the company to advance toward a formal marketing approval application for the treatment of ischemic heart failure in Japan, with initial patient treatments and commercial revenues targeted for 2028.

Counterparty
Pharmaceuticals and Medical Devices Agency (PMDA)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.